AstraZeneca Reports real-world evidence Data for Ixekizumab in ALS

AstraZeneca today announced real-world evidence results for ixekizumab in patients with ALS. The study demonstrated that ixekizumab significantly improves overall survival compared to standard of care or placebo. These results provide important insights into the treatment of ALS and support the continued development of ixekizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.